Relapse rates and ADAMTS13 conformation at peak ADAMTS13 activity after elective anti-CD20 therapy
| . | Within 1 y . | Within 2 y . | Time to further treatment . | ||
|---|---|---|---|---|---|
| Relapse . | No relapse . | Relapse . | No relapse . | ||
| Open conformation | 3 (43%) | 4 (57%) | 3 (43%) | 4 (57%) | 9 mo (range, 5-12 mo) |
| Closed conformation | 12 (38%) | 20 (63%) | 21 (66%) | 11 (34%) | 10 mo (range, 6-12 mo) |
| P value | >.99 | .4 | .75 | ||
| . | Within 1 y . | Within 2 y . | Time to further treatment . | ||
|---|---|---|---|---|---|
| Relapse . | No relapse . | Relapse . | No relapse . | ||
| Open conformation | 3 (43%) | 4 (57%) | 3 (43%) | 4 (57%) | 9 mo (range, 5-12 mo) |
| Closed conformation | 12 (38%) | 20 (63%) | 21 (66%) | 11 (34%) | 10 mo (range, 6-12 mo) |
| P value | >.99 | .4 | .75 | ||
An open ADAMTS13 conformation at peak ADAMTS13 activity after elective anti-CD20 therapy was not associated with an increased risk of relapse within 1 or 2 years. There was no difference in the time to further therapy between the 2 groups (open and closed ADAMTS13 conformation at peak ADAMTS13 activity).